Table S1. Summary of key inclusion and exclusion criteria for the EDITION 1, 2, and 3 trials Key Trial participant EDITION 1 [1] EDITION 2 [2] EDITION 3 [3] criteria Inclusion Age 18 trial Age 18 years Age 18 years ≥ ≥ ≥ Type 2 diabetes (WHO definition) Type 2 diabetes (WHO for Type 2 diabetes (WHO definition) for 1 year before screening 1 year before screening ≥ ≥ Use of basal and mealtime insulin therapy ± MET year 6 months on basal insulin therapy Use of OADs for 6 months before ≥1 ≥ ≥ screening* Basal therapy units/day of either Gla100 Recent use (within the last 4 weeks) of ≥42 or NPH units/day of Gla-100 or NPH combined Insulin naïve ≥42 with OAD(s) Mealtime therapy with insulin lispro, aspart, or glulisine HbA1c 7.0–10.0 % (53–86 mmol/mol) Exclusion Use of human mealtime insulin or any HbA1c < 7.0 % (<53 mmol/mol) or > 10 % < 7.0 % (<53 mmol/mol) or >11.0 % premixed or basal insulin other than Gla or (>86 mmol/mol) within the past 3 months (>97 mmol/mol) at screening NPH Use of premixed insulin, insulin detemir, or Oral glucose-lowering drugs other than MET new glucose-lowering agents within the past in the last 3 months 2 months Injected glucose-lowering agents other than Use of sulfonylurea for >10 days in the past insulin 3 months
Table S1. Summary of key inclusion and exclusion criteria for the EDITION 1, 2, and 3 trials Key participant criteria Trial EDITION 1 [1] EDITION 2 [2] EDITION 3 [3] Inclusion Age ≥ 18 Type 2 diabetes (WHO Use of basal and mealtime insulin therapy ± MET ≥1 year Basal therapy ≥42 units/day of either Gla100 or NPH Mealtime therapy with insulin lispro, aspart, or glulisine HbA1c 7.0–10.0 % (53–86 mmol/mol) Age ≥ 18 years Type 2 diabetes (WHO definition) for ≥ 1 year before screening ≥ 6 months on basal insulin therapy Recent use (within the last 4 weeks) of ≥42 units/day of Gla-100 or NPH combined with OAD(s) Age ≥ 18 years Type 2 diabetes (WHO definition) for ≥ 1 year before screening Use of OADs for ≥ 6 months before screening* Insulin naïve Exclusion Use of human mealtime insulin or any premixed or basal insulin other than Gla or NPH Oral glucose-lowering drugs other than MET in the last 3 months Injected glucose-lowering agents other than insulin HbA1c < 7.0 % (<53 mmol/mol) or > 10 % (>86 mmol/mol) within the past 3 months Use of premixed insulin, insulin detemir, or new glucose-lowering agents within the past 2 months Use of sulfonylurea for >10 days in the past 3 months < 7.0 % (<53 mmol/mol) or >11.0 % (>97 mmol/mol) at screening trial
1-s2.0-S1262363617305839-mmc2.docx